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Abstract
The balance between pro-inflammatory and regulatory immune responses in determining optimal T cell activation is vital
for the successful resolution of microbial infections. This balance is maintained in part by the negative regulators of T cell
activation, CTLA-4 and PD-1/PD-L, which dampen effector responses during chronic infections. However, their role in acute
infections, such as malaria, remains less clear. In this study, we determined the contribution of CTLA-4 and PD-1/PD-L to the
regulation of T cell responses during Plasmodium berghei ANKA (PbA)-induced experimental cerebral malaria (ECM) in
susceptible (C57BL/6) and resistant (BALB/c) mice. We found that the expression of CTLA-4 and PD-1 on T cells correlates
with the extent of pro-inflammatory responses induced during PbA infection, being higher in C57BL/6 than in BALB/c mice.
Thus, ECM develops despite high levels of expression of these inhibitory receptors. However, antibody-mediated blockade
of either the CTLA-4 or PD-1/PD-L1, but not the PD-1/PD-L2, pathways during PbA-infection in ECM-resistant BALB/c mice
resulted in higher levels of T cell activation, enhanced IFN-c production, increased intravascular arrest of both parasitised
erythrocytes and CD8+ T cells to the brain, and augmented incidence of ECM. Thus, in ECM-resistant BALB/c mice, CTLA-4
and PD-1/PD-L1 represent essential, independent and non-redundant pathways for maintaining T cell homeostasis during a
virulent malaria infection. Moreover, neutralisation of IFN-c or depletion of CD8+ T cells during PbA infection was shown to
reverse the pathologic effects of regulatory pathway blockade, highlighting that the aetiology of ECM in the BALB/c mice is
similar to that in C57BL/6 mice. In summary, our results underscore the differential and complex regulation that governs
immune responses to malaria parasites.
Citation: Hafalla JCR, Claser C, Couper KN, Grau GE, Renia L, et al. (2012) The CTLA-4 and PD-1/PD-L1 Inhibitory Pathways Independently Regulate Host Resistance
to Plasmodium-induced Acute Immune Pathology. PLoS Pathog 8(2): e1002504. doi:10.1371/journal.ppat.1002504
Editor: E. John Wherry, University of Pennsylvania, United States of America
Received June 14, 2011; Accepted December 11, 2011; Published February 2, 2012
Copyright:  2012 Hafalla, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: JCRH was a recipient of a Royal Society (UK) Incoming Fellowship and a Wellcome Trust Visiting Fellowship (WT079920), and is currently supported by a
Royal Society (UK) University Research Fellowship. JBdS was funded by a European Union FP6 Project (LSHP-CT-2006-037749). GEG is funded by ARC DISCOVERY
DP0774425, NHMRC PROJECT GRANT 464893 and NHMRCEU collaborative GRANT 512101. LR is supported by an intramural grant fromA*STAR, Singapore. The
funders had no role in study design, data collection andanalysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Julius.Hafalla@lshtm.ac.uk
. These authors contributed equally to this work.
Introduction
The outcome of microbial infections is dependent on the
balance between pro-inflammatory and regulatory immune
responses. Priming of naı¨ve T cells and their differentiation into
effector cells needs to be balanced by switching off these cells, at an
appropriate stage of infection, in order to prevent tissue damage
(immune pathology). Two important T cell inhibitory pathways
involve signalling through members of the CD28:B7 superfamily
of costimulatory molecules, namely cytotoxic T lymphocyte
antigen-4 (CTLA-4; CD152) and programmed death-1 (PD-1;
CD279). While CTLA-4 is expressed on activated T cells
including regulatory T cells [1–3], PD-1 is broadly expressed on
activated T cells, regulatory T cells and other haematopoietic cells
[4]. T cell activation through the T cell receptor (TCR) and the
costimulatory molecule CD28 results in increased expression of
CTLA-4 [1]. Since both CD28 and CTLA-4 bind to B7-1 (CD80)
and B7-2 (CD86) on antigen-presenting cells [5–7], sequential
expression of CD28 and then CTLA-4 allows T cells to be
intrinsically self-regulating. CTLA-4 has higher affinity to the B7
molecules than CD28. Similarly, PD-1 binds to PD ligand 1 (PD-
L1; CD274) and 2 (PD-L1; CD273) which are upregulated on
activated macrophages and dendritic cells (DCs) [4]. In addition,
PD-L1, which is also expressed on activated T cells, has recently
been shown to bind B7-1 [8], suggesting that there may be
opportunities for cross-talk between the CTLA-4/B7 and PD-1/
PD-L1 pathways. Consistent with their roles in the physiological
regulation of cellular immune responses, CTLA-42/2 and PD-12/
2 mice develop spontaneous autoimmune diseases; CTLA-42/2
mice die 2–3 weeks after birth from systemic lymphoproliferation
[9,10] while PD-12/2 mice develop lupus-like glomerulonephritis
and destructive arthritis [11,12].
PLoS Pathogens | www.plospathogens.org 1 February 2012 | Volume 8 | Issue 2 | e1002504
Accumulating data suggest that PD-1/PD-L1 signalling, and in
some cases CTLA-4 signalling, is implicated in the T cell
exhaustion that is seen in many chronic infections [13–15]. For
example, expression of PD-1 is associated with progressive loss of
CD8+ T cell effector function during persistent lymphocytic
choriomeningitis virus (LCMV) infection in mice; blockade of PD-
1/PD-L1 interactions but not the CTLA-4 pathway augmented T
cell function and allowed the virus to be controlled [16]. Similarly,
in humans, PD-1 is upregulated on both CD4+ and CD8+ T cells
during human immunodeficiency virus (HIV) infection and on
CD8+ T cells during hepatitis C virus (HCV) infections and is
associated with functional impairment of T cells and disease
progression [17–19]. In vitro blockade of PD-1/PD-L1 pathway
significantly increases CD8+ and CD4+ T cell function during HIV
infection [20]. There is limited information available on the role of
the PD-1/PD-L2 in chronic infections. In vitro blockade of PD-1/
PD-L1 and to a lesser extent PD-1/PD-L2 resulted in reversal of
immune dysfunction in HCV [21]. PD-L2 expression on dendritic
cells is correlated to morbidity in experimental chronic schistoso-
miasis [22]. High levels of CTLA-4 expression are found on HIV-
specific CD4+ T cells, but not on CD8+ T cells, and in vitro
blockade of CTLA-4 enhances HIV-specific CD4+ T cell function
[17]. Likewise, CTLA-4 blockade augments T cell responses to,
and resolution of chronic infections such as Helicobacter pylori [23],
Leishmania donovani [24], Leishmania chagasi [25] and Trypanosoma
cruzi [26] in mice.
With regard to acute infections, CTLA-4 blockade during
Nippostrongylus brasiliensis [27] and Listeria monocytogenes [28] infection
greatly enhanced T cell responses, resulting in more effective
infection control. However, although CTLA-4 blockade enhanced
T cell responses during Mycobacterium bovis infection, this did not
have any effect on bacterial clearance [29]. PD-L12/2 mice are
markedly more resistant to rabies virus [30] and Histoplasma
capsulatum infection [31] than are wild-type mice. While these
studies clearly indicate a role for the PD-1/PD-L1 pathway in
dampening T cell responses, there is, rather confusingly, some
evidence that this pathway is important in promoting CD8+ T cell
responses in murine influenza virus [32] and Listeria monocytogenes
[33] infections, suggesting that the outcome of PD-1/PD-L1
interactions might be modified by other regulatory pathways.
Moreover, in Plasmodium yoelii malaria infections, CTLA-4
blockade increased T cell activation and IFN-c production leading
to early resolution of infections with the non-lethal 17X strain, but
to increased severity of infections with the highly virulent 17XL
strain of the parasite [34], suggesting that enhancing T cell
activation can be beneficial in relatively mild infections but can
exacerbate virulent infections. Limited data are available for the
PD-1/PD-L2 pathway during acute infections: PD-1/PD-L2 but
not PD-1/PD-L1 blockade favours trypanosomatid growth in
macrophages [35] and PD-L2 blockade enhances Th2 responses
during Nippostrongylus infection [36].
Very few studies have directly contrasted the roles of CTLA-4
and PD-1 in the same infection, investigated the role of these
pathways in determining susceptibility or resistance to infection in
different mouse strains, or evaluated the extent to which they
modulate immune pathology versus pathogen clearance. Here we
have directly compared the roles of the CTLA-4 and PD-1
pathways in an acute malaria infection model in which resistance
or susceptibility to immune-mediated pathology varies among
strains of mice.
P. berghei ANKA (PbA) infection of experimental cerebral
malaria (ECM)-susceptible C57BL/6 mice reproduces the neuro-
logical signs associated with human cerebral malaria, the most
severe complication of infection by the human parasite, P.
falciparum [37]. Ante-mortem, the diagnostic neurological signs of
ECM are ataxia and/or paralysis, which quickly leads to seizures,
prostration and death within 10 days of infection. Histologically,
CM is characterised by oedema, petechial haemorrhages and
adherence of leucocytes and parasitised red blood cells to brain
endothelium [37]. The essential triggers for ECM include systemic
priming of CD4+ T cells by conventional DCs [37], the production
of pro-inflammatory cytokines such as IFN-c [38,39], the
recruitment of effector CD8+ T cells to the brain [40,41], and
parasite accumulation in the cerebral microvasculature [42–44].
C57BL/6 mice infected with PbA develop a multi-organ disease as
recently described [45] and – as in the brain - this is mediated by T
cells and IFN-c. However, this systemic disease, in the absence of
cerebral involvement, does not appear to be fatal and mice will die
at a later time point from hyperparasitaemia. The current best
model of the pathogenesis of ECM is that CD8+ T cells damage
cerebral vascular endothelial cells and the underlying basement
membrane, thereby breaching the blood brain barrier, causing
haemorrhage and oedema. Thus, pathology manifests initially in
the brain because this organ is particularly vulnerable to the
immediate consequences of endothelial damage.
In contrast, the majority of PbA-infected BALB/c mice do not
develop ECM but die from high parasitaemia and anaemia 2–3
weeks post-infection [46]. Hence, BALB/c mice are considered
resistant to PbA-induced immune pathology. We hypothesised,
therefore, that T cell-mediated inflammatory responses may be
down-regulated in BALB/c mice (preventing control of parasitae-
mia but also preventing accumulation of T cells in the brain), and
that this might be due to differential regulation of CD4+ and/or
CD8+ T cells by CTLA-4 and/or PD-1. We found that in C57BL/
6 mice, ECM develops despite high levels of expression of
inhibitory receptors on CD4+ and CD8+ T cells. Conversely, we
found that blockade of either CTLA-4 or PD-1/PD-L1, but not
PD-1/PD-L2, during PbA-infection leads to the onset of ECM in
normally resistant BALB/c mice and that this is accompanied by
the characteristic features of T cell hyperactivity, raised IFN-c
levels and accumulation of CD8+ T cells and parasites in the brain.
Thus, the CTLA-4 and PD-1/PD-L1 pathways seem to function
Author Summary
T cells are part of the body’s defense system in response to
infection. However, once the infection has been suitably
controlled, these T cells must be switched off. Inhibitory
pathways, such as CTLA-4 and PD-1, are known to send the
‘turn off’ signal to T cells during chronic infections.
However, their roles in acute infections, such as malaria,
are unclear. We compared the function of these inhibitory
pathways in mice that are either susceptible or resistant to
severe malarial disease (cerebral malaria). Strikingly, we
found that receptors for CTLA-4 and PD-1 are more highly
expressed in T cells from susceptible mice than from
resistant mice. Therefore, cerebral malaria develops
despite the high expression of these inhibitory receptors.
Moreover, we demonstrated that blocking these inhibitory
receptors in the resistant mice increased the function of T
cells, which in turn led to the characteristic signs of
cerebral malaria. Finally, reminiscent of what is known for
the susceptible strain, we confirmed that certain T cells
(CD8+) and molecules (IFN-c) are crucial to the develop-
ment of cerebral malaria in the otherwise resistant mice.
Thus, the CTLA-4 and PD-1 inhibitory pathways have
essential, independent and non-redundant roles in regu-
lating the body’s complex response to malaria.
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very efficiently in BALB/c mice, maintaining the balance between
immunity and immune pathology during the critical early stage of
infection.
Materials and Methods
Ethics statement
Animal experiments performed in the United Kingdom were
approved by the LSHTM Animal Procedures and Ethics
Committee and were performed under licence from the United
Kingdom Home Office under the Animals (Scientific Procedures)
Act 1986. In Singapore, all experiments and procedures were
approved by the Institutional Animal Care and Use Committee
(IACUC) of A*STAR (Biopolis, Singapore) (Authorization No
IACUC 080321) in accordance with the guidelines of the Agri-
Food and Veterinary Authority (AVA) and the National Advisory
Committee for Laboratory Animal Research (NACLAR) of
Singapore.
Mice, parasites and experimental infections
Six- to twelve week old BALB/cAnNCrl mice and C57BL/
6NCrl mice were purchased from Charles River UK Ltd and
maintained under barrier conditions. PbA parasites, derived from
the PbA clone 15cy1, which had been genetically engineered to
express green fluorescent protein (PbAgfp [47], referred to here as
PbA) were maintained by passage through naı¨ve mice. For in vivo
imaging experiments, seven- to eight weeks old BALB/cJ mice
were bred in-house and kept under specific pathogen-free
conditions. Transgenic P. berghei ANKA 231c1l parasites
expressing luciferase under the control of the ef1-a promoter
(referred here as PbAluc) were provided by Dr. Christian
Engwerda (Queensland Institute for Medical Research, Brisbane,
Australia) from a stock originally from Leiden, The Netherlands
[48,49].
Experimental infections were initiated by i.v. inoculation of 104
PbA-parasitised red blood cells (pRBC) and infected mice were
monitored for neurological symptoms (paralysis, ataxia, convul-
sions, and coma occurring between day 6 and 10 post-infection) as
previously described [50]. All mice that developed signs of
irreversible pathology were immediately humanely sacrificed and
their brains examined for signs of ECM (see Protocol S1 in Text
S1 for additional details). Cumulative ECM incidence during the
observation period was then reported. Parasitaemia was deter-
mined by examination of Giemsa-stained thin blood smears. On
various days post-infection, mice were sacrificed and exsanguinat-
ed. Moreover, their spleens were removed, and single spleen cell
suspensions were prepared by homogenisation through a 70 mm
cell strainer (BD Biosciences). CD4+ and CD8+ T cells were
purified by magnetic bead sorting (MACS, Miltenyi Biotec). Brain-
sequestered leucocytes were isolated from perfused animals as
described [51]. Live cells were counted by trypan blue exclusion.
Heparinised plasma was stored at 270uC for cytokine quantifi-
cation.
In vivo administration of antibodies
Blocking antibodies to CTLA-4 [UC10-4F10-11], PD-L1 [9G2]
and PD-L2 [TY5] and neutralising antibodies to IFN-c [XMG1.2]
and TNF [XT3.11] were administered by intraperitoneal injection
(0.4 mg/mouse) on days 21, 1, 3, 5 and 7 of infection. Depleting
antibodies to CD4 [GK1.5] and CD8 [53.6.72] were administered
by intraperitoneal injection (0.25 mg/mouse) on days21, 1, 4 and
6 (or on days 4 and 6) of infection. All antibodies were rat-a-mouse
IgG and were obtained from BioXCell; control rat IgG was
obtained from Pierce.
Flow cytometry
Antibodies [clones] for cell-surface staining were obtained from
eBiosciences (a-mouse CD4 [GK1.5], CD8 [53.6-7], CD11a
[M17/4], CD11c [N418], CD44 [IM7], CD62L [MEL-14],
CD71 [R17217], CD273/PD-L2 [122], CD274/PD-L1 [MIH5],
CD279/PD-1 [RMP1-30]), F4/80 [BM8] or BD Biosciences (a-
mouse CD3 [145-2C11], CD4 [RM4-5] and CD8 [53-6.7]).
Isolated leucocytes were directly stained according to standard
protocols. Antibodies for intracellular staining were obtained from
eBiosciences (a-mouse CD152/CTLA4 [UC10-4B9], FoxP3 [FJK-
16s], and IFN-c [XMG1.2]). Intracellular staining was performed
by permeabilising cells with 0.1% Saponin/PBS. Cells were
analysed using a FACSCalibur or LSR II (BD Immunocytometry
Systems) and FlowJo software (TreeStar).
Cytokine quantification
Plasma cytokines were assayed by cytometric bead array (mouse
inflammation kit; BD Bioscience) following the manufacturer’s
protocol. Intracellular IFN-c was assayed by flow cytometry
(above) following 5-hour culture of mixed spleen cells in the
presence of PMA (50 ng/mL), ionomycin (1 mg/mL), and
Brefeldin A (1 mg/mL). Secreted IFN-c and IL-10 were assayed
by conventional ELISA [52] in supernatants of purified CD4+ or
CD8+ T cells cultured (at 105 cells per well) for 24 or 48 hours
respectively in the presence of a-CD3 [clone 145-2C11, 1 mg/mL]
and a-CD28 [clone 37.51, 1 mg/mL] antibodies (eBioscience).
Histopathology
Brain and liver tissues were fixed in 10% formaldehyde saline,
paraffin-wax embedded, sectioned, stained with haematoxylin and
eosin and examined by light microscopy at 20X magnification.
Bioluminescent imaging
Distribution of PbAluc parasites was monitored daily by in vivo
imaging (IVIS; Xenogen, Alameda, California). Infected mice
were anaesthesised, injected s.c. with 100 ml of D-luciferin
potassium salt (Caliper Life Sciences) (5mg/ml in PBS) and, two
minutes later, bioluminescence images were acquired, with
medium binning factor and fields-of-view (FOV) of 21.7 and
4 cm for the whole body (ventral) and head (dorsal), respectively.
Imaging time was between 5 to 60 seconds per mouse. In terminal
experiments, mice were given a second injection of luciferase
substrate and, within 3 minutes, mice were sacrificed (by cervical
dislocation). Brains were removed and imaged with 10 cm FOV.
To allow comparison of images from different days of the
experiment, uninfected mice injected with luciferin were imaged
for background subtraction. Bioluminescence in the brains was
quantified using Living Imaging 3.0 software and expressed as
average radiance units (p/s/cm2/sr).
Statistical analysis
Statistical analysis was performed in GraphPad Prism (Graph-
Pad Software Inc). Comparisons between two groups were made
using the Mann Whitney test. For comparisons involving more
than two groups, statistical significance was determined using the
Kruksal Wallis test with Dunn’s post-test for multiple comparisons
with p,0.05 taken as evidence of a significant difference.
Differences in survival curves between two groups were analysed
using the Log-rank (Mantel Cox) test. Differences in cumulative
ECM incidence between two groups was analysed using the
Fisher’s exact test. Bonferroni correction was used to adjust for
multiple comparisons within the Log-rank (Mantel Cox) and
Fisher’s exact tests. The Bonferroni-corrected threshold for
Regulation of Malaria Acute Immune Pathology
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significance was calculated by dividing the conventionally set level
of significance (0.05) by the number of comparisons.
Results
Expression of the inhibitory receptors CTLA-4 and PD-1
correlates with the induction of pro-inflammatory
responses during PbA infection in both ECM-resistant
and ECM-susceptible mouse strains
The course of PbA infection was compared in C57BL/6 and
BALB/c mice (Figure 1A). PbA-infected C57BL/6 mice became
moribund on day 7 post-infection after developing neurological
signs. In contrast, the majority of PbA-infected BALB/c mice
survived up to day 15 post-infection when they were euthanised
due to the development of severe anaemia and moderate
parasitaemia. Over the course of three experiments, 100% (12/
12) of C57BL/6 mice but only 25% (4/16) of BALB/c mice
developed signs of ECM (Figure 1B). There was no difference
between C57BL/6 and BALB/c mice in peripheral parasitaemia
up to day 7 (Figure 1C).
To determine if T cell regulatory receptors could explain
differences in susceptibility to ECM, intracellular expression of
CTLA-4 and surface expression of PD-1 were compared on
splenic T cells of BALB/c and C57BL/6 mice at different times
after PbA infection (Figure 2). The proportions of CD4+ and
CD8+ T cells expressing either CTLA-4 or PD-1 were similar in
the two mouse strains during the first 6 days of infection, but
surprisingly, on day 7 – i.e. at exactly the time when susceptible
mice began to show signs of ECM – the proportions of both CD4+
and CD8+ T cells expressing CTLA-4 and PD-1 were significantly
higher in ECM-susceptible C75BL/6 mice than in ECM-resistant
BALB/c mice (Figure 2A, B). Consistent with previous reports in
other models that PD-L1 is also expressed on T cells and is further
upregulated during activation [4], PD-L1 was upregulated on
virtually all CD4+ and CD8+ T cells by day 5 of PbA infection in
both C57BL/6 and BALB/c mice (Figure S1A in Text S1). In
addition, dendritic cells (Figure S1B in Text S1) and macrophages
(Figure S1C in Text S1) from both groups of mice upregulated
PD-L1 and PD-L2 during infection.
The higher frequency of CTLA-4hi and PD-1hi cells in infected
C57BL/6 mice correlated with a higher proportion of CD4+ and
CD8+ splenic T cells able to secrete IFN-c (Figure 2C).
Furthermore, T cells from C57BL/6 mice expressed significantly
higher levels of effector and activation markers: CD11ahi, a
surrogate marker for polyclonal, antigen-experienced CD8+ T
cells [53,54] and CD62Llo, a commonly used marker of effector
cells [53,55] (Figure S2 in Text S1).
In both strains of infected mice, and in both CD4+ and CD8+ T
cells, CTLA-4 and PD-1 seem to be co-expressed on the same cells
(Figure 2D, Figure S3 in Text S1), indicating that the two
receptors may function co-operatively. Consequently, CTLA-4hi/
PD-1hi expression on T cells coincided with CD11ahi (Figure
S3B,E in Text S1) and CD62Llo (Figure S3C,F in Text S1)
suggesting that these are activated cells induced in response to
infection. Moreover, the vast majority of CTLA-4hi and PD-1hi
CD4+ T cells were FoxP3-, indicating that they are not classical
regulatory T cells (Figure 2E,F).
Together, these data indicate that CTLA-4, PD-1 and PD-L1
are upregulated on activated T cells during PbA infection in both
ECM-susceptible and ECM-resistant mice. However, the very
high degree of T cell activation in C57BL/6 mice may provide a
situation where positive signals override physiological levels of
immune regulation mediated by CTLA-4 and PD-1 such that they
are unable to prevent immune-mediated pathology.
Blockade of CTLA-4 and PD-1/PD-L1 pathways induces
experimental cerebral malaria in otherwise resistant mice
To determine whether the CTLA-4 and PD-1 pathways
modulate ECM pathogenesis in the ECM-resistant strain, the
outcome of PbA infection was compared between control mice and
mice treated with blocking antibodies to PD-L1 or CTLA-4. We
decided to focus on CTLA-4 and PD-1/PD-L1 particularly
because both of these inhibitory pathways have been extensively
studied in chronic infections but a comparison of the two pathways
during an acute infection was lacking.
BALB/c mice treated with either a-CTLA-4 (20/20; 100%) or
a-PD-L1 (20/22; 90.9%) developed classical neurological signs of
ECM and were euthanised on days 7–8 post-infection or days 8–
10 post-infection, respectively, whereas control mice (treated with
rat IgG or PBS) survived for up to two weeks and were euthanised
due to severe anaemia (Figure 3A, B). Importantly, antibody
treatment had no effect on parasitaemia (Figure 3C). The
survival curves for a-CTLA-4 and a-PD-L1-treated mice differ
significantly from the control mice. In addition, the survival curves
for a-CTLA-4 and a-PD-L1-treated mice were also significantly
different from each other. Since PD-1 also binds another ligand,
PD-L2, the outcome of PbA infection was compared between
control mice and mice treated with a-PD-L2. As shown in Figure
S4 in Text S1, a-PD-L2 treatment had no effect on the course of
infection or the pathological outcome of PbA-infection in BALB/c
mice.
Consistent with their development of neurological signs of
ECM, numbers of arrested CD8+ T cells were significantly higher
in brain microvessels of a-CTLA-4-treated and a-PD-L1-treated
BALB/c mice than in brains of control mice (Figure 3D).
Moreover, histological examination revealed more frequent
Figure 1. Course of infection of Plasmodium berghei ANKA (PbA)
in C5BL/6 (ECM-susceptible) and BALB/c (ECM-resistant) mice.
Mice were infected i.v. with 104 PbA pRBCs. The course of infection in
C57BL/6 (n = 12) and BALB/c (n = 16) mice was followed by monitoring:
(A) Cumulative survival – C57BL/6 (N) and BALB/c (#), *** P,0.0001
(Log-rank (Mantel Cox) test); and (B) Development of experimental
cerebral malaria (ECM; cumulative incidence during the observation
period), *** P,0.0001 (Fisher’s exact test). The incidence of ECM was
based on neurological signs, i.e. ataxia and paralysis. This was confirmed
by histopathological examination of the brain. Surviving BALB/c mice
were euthanized on day 15 due to the development of high
parasitaemia and anemia; these mice were not ataxic or paralysed
and they did not have brain lesions. (C) Parasitaemias are shown as
mean + SD; representative of three experiments (four to six mice per
group in each experiment). (D) H&E histopathology of brains from
uninfected (left panel) and day 7 infected (right panel) C57BL/6 mice.
Blue arrow indicates an area of haemorrhage. Magnification = 20X.
doi:10.1371/journal.ppat.1002504.g001
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petechial haemorrhages and a higher proportion of cerebral blood
vessels plugged with parasitised red blood cells in brains of BALB/
c mice treated with a-CTLA-4 or a-PD-L1 antibodies than in
brains of control (treated with rat IgG or PBS or left untreated)
mice (Figure 3E, Table 1) as well as increased numbers of
pigmented (parasite-containing) macrophages in their livers
(Table 1).
The accumulation of parasitised erythrocytes in the microvas-
culature of the brain is a cardinal feature of cerebral pathology in
both human cerebral malaria [56] and ECM in mice [42,43]. To
further quantify the effects of CTLA-4 and PD-L1 blockade on
parasite accumulation, a-CTLA-4- and a-PD-L1 antibody-
treated BALB/c mice (and controls) were infected with PbAluc
(transgenic PbA expressing luciferase) and whole body, head and
brain parasite burdens were quantified by bioluminescence at the
onset of signs of ECM. The course of PbAluc infection in control,
a-PD-L1- and a-CTLA-4-treated mice (Figure 4A–C) was
similar to the course of PbA infection (Figure 3A–C), confirming
that insertion of the luciferase gene had not significantly altered
the basic biology of the parasite, although the onset of ECM was
slightly delayed (a-CTLA-4-treated mice developed ECM on day
10 post infection; a-PD-L1-teated mice developed ECM on day
11 and control mice were euthanised on day 18). Nevertheless,
after day 7 of infection, whole body (Figure 4D), head
(Figure 4E) and isolated brain (Figure 4F,G) parasite burdens
were significantly higher in a-CTLA-4- and a-PD-L1-treated
mice than in control mice. It should be noted that the detection of
a weak luminescence signal in the brains of control (no ECM)
mice in Figure 4F simply reflects the presence of luminescent
parasites in the circulating blood in all organs. These results show
that, despite similar peripheral parasite burden in control and
antibody-treated mice, overall parasite biomass is significantly
increased when the CTLA-4/PD-1 regulatory pathways are
blocked.
Taken together, these data indicate that blockade of either the
inhibitory receptor CTLA-4 or PD-L1, leads to striking immune
pathology, with all the phenotypic characteristics of ECM, in
otherwise ECM-resistant mice.
Figure 2. Differential expression of CTLA-4 and PD-1 by T cells of PbA-infected C5BL/6 and BALB/c mice. Mice were infected i.v. with
104 PbA pRBCs. Splenocytes were prepared from uninfected (solid curves) or day 7 infected (clear curves) mice and stained for CD4 (left) or CD8 (right)
expression of (A) CTLA-4 or (B) PD-1. For CTLA-4, staining was for both surface and intracellular protein; for PD-1, staining was for surface expression
only. Line graphs show the kinetics of expression during the first 7 days of infection: data points (mean 6 SD) from C57BL/6 (N) and BALB/c (#);
n = 6, ** P,0.01 and *** P,0.001, P-values (Mann Whitney U test). (C) CD4+ and CD8+ T cells from uninfected and day 7 infected mice were stained
for intracellular IFN-c following stimulation with PMA/Ionomycin in the presence of Brefeldin A. CD4+ T cells were directly stained ex vivo for
(D) intracellular CTLA-4 and surface PD-1; (E) CTLA-4 and intracellular FoxP3 or (F) surface PD-1 and intracellular FoxP3. Data for (C) and (D) are
representative of three independent experiments with three to six mice in each group. Data for (E) and (F) are representative of two independent
experiments with three mice in each group.
doi:10.1371/journal.ppat.1002504.g002
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Effector responses are enhanced following CTLA-4 and
PD-L1 blockade
Since ECM is known to be a consequence of T cell-mediated
inflammation in susceptible C57BL/6 mice[57], the development
of neurological signs of ECM - together with CD8+ T cell
infiltration and parasite accumulation in the microvasculature of
the brain - in PbA-infected BALB/c mice after a-CTLA-4 or a-
PD-L1 antibody treatment was suggestive of an enhanced
inflammatory T cell response. To explore this hypothesis, we
assessed levels of splenic T cell activation on day 7 post-infection
(Figure S5 in Text S1). The proportions of splenic CD4+ and
CD8+ T cells expressing an activated phenotype [CD71+
(transferrin receptor) and CD4+ T cells expressing CD44+ (Pgp-
1)] were generally higher in a-CTLA-4-treated than in control
Figure 3. CTLA-4 and PD-1 blockade in PbA-infected BALB/c mice leads to onset of ECM. BALB/c mice were infected i.v. with 104 PbA
pRBCs and treated with a-CTLA4 or a-PD-L1 antibodies or with no antibody. (A) Cumulative survival curve: X = Control (n = 31);&= a-CTLA-4 (n = 20);
%=a-PD-L1 (n = 22), P-values (Log-rank (Mantel Cox) test). (B) Cumulative incidence of mice developing ECM, P-values (Fisher’s exact) test.
Bonferroni correction was used to adjust for multiple comparisons; threshold for significance is P,0.017 for (A) and (B). The incidence of ECM was
based on neurological signs, i.e. ataxia and paralysis. Surviving BALB/c mice were euthanized on day 15 due to high parasitaemia and anemia. (C)
Parasitaemia levels, shown as mean 6 SD, of PbA-infected mice: X = Control; &= a-CTLA-4; %= a-PD-L1. Data are representative of three
independent experiments with four to six mice in each group. (D) Absolute numbers of brain infiltrating CD8 T cell lymphocytes. Data (mean 6 SD)
are from two experiments, the numbers of animals are shown; P-values (Kruskal-Wallis Test/Dunn’s multiple comparison test). (E) Histological
examination of H&E stained brain sections from uninfected and day 7 infected mice (control without ECM and treated with ECM). Blue arrows indicate
areas of haemorrhages. Magnification = 20X.
doi:10.1371/journal.ppat.1002504.g003
Table 1. Histological analysis of brain and liver sections.
Brain Liver
Petechial haemorrhages/50 fields1 Plugged vessels/50 fields2 Pigmented macrophages/50 fields3
Control (untreated) 3.865.9 + 15366
a-CTLA-4 46.0610.2 ++/+++ 263633
a-PD-L1 24.964.8 + 218611
1Sections from each mouse were examined and the numbers in 50 fields were recorded.
Control vs a-CTLA-4 p,0.05, Control vs a-PD-L1 p,0.05, a-CTLA-4 vs a-PD-L1 p,0.05.
2Vessels plugged with pRBCs and leucocytes/50 fields: +++= 11–15, ++=6–10, +=1–5.
3Control vs a-CTLA-4 p = 0.01, Control vs a-PD-L1 p = 0.02, a-CTLA-4 vs a-PD-L1 p = 0.07.
doi:10.1371/journal.ppat.1002504.t001
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mice (Figure S5 in Text S1). Notably, the proportions of splenic
CD8+ T cells expressing CD11a+ was generally higher in both a-
CTLA-4 and a-PD-L1-treated mice than in control mice. A trend
was observed for higher proportions of splenic CD8+ T cells to
express CD62L2 and CD11a+ in a-PD-L1-treated than in control
mice. Thus, the slightly earlier onset of ECM in the a-CTLA-4-
treated mice than in the a-PD-L1-treated mice (Figures 3A and
4A) correlates with the slightly higher levels (statistically significant)
of T cell activation in the a-CTLA-4-treated mice.
Indicators of systemic inflammation following CTLA-4
and PD-L1 blockade
Plasma concentrations of cytokines and chemokines (measures
of systemic inflammation) peaked on day 5 after infection
(Figure 5). Plasma concentrations of IFN-c, MCP-1 and IL-10
were significantly higher in a-CTLA-4- and a-PD-L1-treated mice
than in untreated control mice. Concentrations of TNF and IL-6
were significantly higher in a-CTLA-4-treated mice than in either
of the other two groups, and importantly, TNF and IL-6 levels did
not differ between control mice and a-PD-L1-treated mice
(Figure 5A).
To determine whether differences in plasma cytokine levels
were related to differences in CD4+ and CD8+ T cell cytokine
secretion, IFN-c and IL-10 were quantified in culture supernatants
of purified CD4+ and CD8+ T cells stimulated for 48 and
24 hours, respectively with a-CD3/a-CD28 antibodies. CD4+ T
cells isolated on days 5 and 7 post-infection from a-CTLA-4-
treated mice secreted significantly more IFN-c and IL-10 than did
CD4+ T cells from control mice (Figure 5B). In addition, CD4+
T cells isolated from day 5 post-infection from a-PD-L1-treated
mice secreted more IFN-c than did CD4+ T cells from control
mice. Furthermore, CD4+ T cells isolated from a-CTLA-4-treated
mice secreted significantly more IFN-c (day 7) and IL-10 (days 5
and 7) than did CD4+ T cells from a-PD-L1 treated mice.
Similarly, CD8+ T cells isolated from a-CTLA-4 (day 7 post-
infection)- and a-PD-L1 (days 5 and 7 post-infection)-treated mice
secreted significantly more IFN-c than did CD8+ T cells from
control mice (Figure 5C). CD8+ T cells isolated on day 5 post
Figure 4. Onset of ECM after CTLA-4 and PD-1 blockade in PbA-infected BALB/c mice is associated with parasite accumulation in
the brain. BALB/c mice were infected i.v. with 104 PbAluc pRBCs and were either untreated (control) or treated with a-CTLA4 or a-PD-L1 antibodies.
(A) Cumulative survival curve: X =Control (n = 10); &= a-CTLA-4 (n = 10); %= a-PD-L1 (n = 10), P-values (Log-rank (Mantel Cox) test). (B) Cumulative
incidence of mice developing ECM, P-values (Fisher’s exact) test. Bonferroni correction was used to adjust for multiple comparisons; threshold for
significance is P,0.017 for (A) and (B). (C) Parasitaemia, shown as mean6 SD, of PbA-infected mice: X = Control;&=a-CTLA-4;%= a-PD-L1. Data are
representative of two independent experiments performed with 5 mice in each group. (D–G) Kinetics of parasite accumulation in the (D) whole
body, (E) head and (F,G) isolated brain as measured by luciferase activity. X = Control;&= a-CTLA-4;%= a-PD-L1. For D-G, data are shown as mean
6 SD. For D and E, 1 Control vs a-CTLA4 p,0.05, 2 Control vs a-PD-L1 p,0.05, and 3 a-CTLA4 vs a-PD-L1 p,0.05 (Kruskal-Wallis Test/Dunn’s multiple
comparison test). For G, P-values (Mann Whitney U test).
doi:10.1371/journal.ppat.1002504.g004
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infection from a-PD-L1 -treated mice secreted significantly more
IFN-c than did CD8+ T cells from a-CTLA-4 treated mice. As
further confirmation that the changes in IFN-csecretion were due
to changes in T cell function, spleen cells collected from treated
mice on day 7 of infection were analysed by intracellular cytokine
staining following short-term stimulation with PMA/ionomycin
(Figure 5D–G). Consistent with the secreted cytokine data
(above) the proportions of IFN-c+splenic CD4+ and CD8+ T cells
were higher in a-CTLA-4- and a-PD-L1-treated mice than in
control mice.
Development of ECM in BALB/c mice following a-CTLA-4
and a-PD-L1 blockade is T cell-mediated
Blockade of either CTLA-4 or PD-L1 renders normally resistant
BALB/c mice fully susceptible to ECM, and this is associated with
increased levels of activation and inflammatory cytokine secretion
in both the CD4+ and CD8+ T cell populations, consistent with the
hypothesis that signalling through both the CTLA-4 and PD-1
pathways is required to down-regulate T cell reactivity and
thereby prevent ECM. To determine whether CD4+ or CD8+ T
cell populations (or both) are the targets of CTLA-4 and PD-1
mediated regulation, CTLA-4 and PD-L1 blockade were com-
bined with in vivo depletion of CD4+ or CD8+ cells (Figure 6).
Depletion of CD8+ cells before and during PbA infection (a-CD8
antibodies administered on days -1, 0, +4 and +6 of infection; full
course) or just prior to the expected onset of neurological signs (a-
CD8 antibodies administered on Days +4 and +6 of infection; late)
completely abrogated the development of ECM in both a-CTLA-
4-treated (Figure 6A) and a-PD-L1-treated (Figure 6B) mice;
instead, CD8-depleted mice developed severe anaemia and were
euthanised significantly later than non-depleted mice.
In contrast, although depletion of CD4+ cells throughout
infection (a-CD4 antibodies administered on days 21, 0, +4 and
+6 of infection) led to a delay in onset of ECM in a-CTLA-4
treated mice (day 8–11 as compared to day 7–8 in a-CTLA-4
treated mice but were not given a-CD4 antibodies), CD4+
depletion later in infection (a-CD4 antibodies administered on
days +4 and +6 of infection) in a-CTLA-4 treated mice had no
effect on the development of ECM. These results are entirely
Figure 5. Enhanced cytokine secretion in PbA-infected BALB/c mice treated with a-CTLA and a-PD-L1 antibodies. (A) Plasma cytokine
levels as determined by cytometric bead array: X = Control;&= a-CTLA-4-treated;%=a-PD-L1-treated. 1 Control vs a-CTLA4 p,0.05, 2 Control vs a-
PD-L1 p,0.05, and 3 a-CTLA4 vs a-PD-L1 p,0.05. (B,C) IFN-c and IL-10 ELISA of culture supernatants of splenocytes (from day 5 and day 7 infected
mice) cultured for 48 h with a-CD3/CD28 antibodies. Spleens from 3–5 individual mice in each treatment group were pooled and each supernatant
was analysed in triplicate. Mean (SE) values are shown for six wells. Uninfected=bar with horizontal line, Control = bar with vertical line, a-CTLA-
4 = black bar, a-PD-L1 =white bar. (D–G) Intracellular IFN-c staining of splenocytes isolated on day 7 post-infection and stimulated with PMA/
Ionomycin for 5 hours in the presence of Brefeldin A. (D,F) Representative plots. (E,G) IFN-c levels, shown as mean 6 SD, are representative of three
experiments (three to six mice per group in each experiment).
doi:10.1371/journal.ppat.1002504.g005
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consistent with data from C57BL/6 mice indicating that CD4+ T
cells play an essential helper role in priming CD8+ T cells in the
first 4 or 5 days of infection but after this time only CD8+ T cells
are required for initiation of ECM [40].
Among a-PD-L1 treated mice, neither CD4+ depletion
throughout infection nor CD4+ depletion later in infection had
any significant effect on the development of ECM. These results
reveal fundamental differences between the CTLA-4 and PD-1
pathways and suggest that the CD4+ T cells in this infection model
are effectively regulated via the CTLA-4/B-7 pathway but are
relatively unaffected to regulation via the PD-1/PD-L1 pathway.
Moreover, additional pairwise analysis comparing the results of
CTLA-4 blockade and PD-L1 blockade in Figure 6 indicate that
the effects of CTLA-4 blockade and PD-L1 blockade are similar
(i.e. not significantly different) for all treatment regimes with the
exception that CTLA-4 blockade combined with late-stage CD4
depletion is significantly different than is PD-L1 blockade
combined with late-stage CD4 depletion (p = 0.0006; Bonferroni
correction indicates that the threshold for significance is
p = 0.006).
Both IFN-c and TNF have been implicated in the development
of ECM [38,58]. To determine their roles in the induction of
ECM in a-CTLA-4- and a-PD-L1-treated PbA-infected BALB/c
mice, in vivo treatment with neutralising a-IFN-c or a-TNF
antibodies throughout infection (days 21, 1, 3, 5, 7) was
performed (Figure 6 C,D). Among a-CTLA-4 treated mice,
neutralisation of IFN-c abrogated the development of ECM, while
neutralisation of TNF had a small but significant effect on the
survival curve. Among the a-PD-L1 treated mice, neutralisation of
IFN-c also abrogated the development of ECM, but neutralisation
of TNF had no significant effect.
Discussion
Regulation of effector T cell function is crucial for immune
homeostasis during infection. Immune homeostasis is maintained,
in part, by the negative regulators of T cell activation, CTLA-4
and PD-1. While PD-1/PD-L1 - and to some extent the CTLA-4/
B-7 pathway - negatively regulate T cell responses during chronic
infections, their roles in acute infections are much less clear. In
addition, there is limited information available for the role of PD-
1/PD-L2 during infection. The extent to which these pathways
may regulate different aspects of the T cell response to acute
infections in animals with differing susceptibility to immunopa-
thology is not known. Whilst other pathways of immune regulation
may contribute to the outcome of virulent malaria infections, only
modest effects on PbA-induced ECM were observed after IL-10
neutralisation in BALB/c mice [59]. Similarly, depletion of
regulatory T cells using a-CD25 antibodies did not increase
mortality rates in BALB/c mice during primary infection with PbA
[60]. Therefore, in this study, we directly compared the roles of the
CTLA-4 and PD-1/PD-L pathways during acute infection with a
Figure 6. T cell depletion or cytokine blockade abrogates the effects of CTLA-4 and PD-L1 blockade in PbA-infected BALB/c mice.
BALB/c mice were infected i.v. with 104 PbA pRBCs and were treated with (A,C) a-CTLA or (B,D) a-PD-L1 antibodies. (A,B) CTLA-4 or PD-L1 blockade
without T cell depletion (%,&); with a-CD8 depletion throughout infection (h,.); with a-CD8 depletion early in infection (g,m); with a-CD4
depletion throughout infection (e,X); or with a-CD4 depletion early in infection (#,N). Cumulative survival curves (left) and cumulative incidence of
ECM (right). (C,D) CTLA-4 or PD-L1 blockade without cytokine blockade (%,&) or with a-IFN-c ( ) or a-TNF ( ) treatment on on days 21, 1, 3, 5 and
7. Cumulative survival curves (left) and cumulative incidence of ECM (right). Data are representative of two independent experiments performed with
four mice in each group. P values: Log-rank (Mantel Cox) test for the survival curves, and Fisher’s exact test for cumulative ECM incidence. Bonferroni
correction was used to adjust for multiple comparisons; threshold for significance is P,0.01 for the T cell depletions and P,0.017 for the cytokine
neutralisations.
doi:10.1371/journal.ppat.1002504.g006
Regulation of Malaria Acute Immune Pathology
PLoS Pathogens | www.plospathogens.org 9 February 2012 | Volume 8 | Issue 2 | e1002504
virulent rodent malaria parasite, PbA in ECM-susceptible
(C57BL/6) and ECM-resistant (BALB/c) mice.
We initially hypothesised that inadequate T cell expression of
CTLA-4 and PD-1 during infection, leading to overproduction of
Th-1 cytokines and migration of activated CD8+ T cells to the
brain, could explain susceptibility to ECM. Interestingly, contrary
to our expectations, proportions of CD4+ and CD8+ T cells
expressing CTLA-4 and PD-1 were significantly higher in ECM-
susceptible C57BL/6 mice than in ECM-resistant BALB/c mice,
and CTLA-4 and PD-1 expression were positively correlated with
IFN-c secretion as well as with the CD11ahi and CD62Llo
phenotype. Indeed, CTLA-4 and PD-1 expression coincided with
expression of the activation markers CD11ahi and CD62Llo. The
expression of both CD11ahi and CD62Llo were used as surrogate
T cell activation markers due to a paucity of defined CD8+ or
CD4+ T cell epitopes associated with pathological responses.
Besides the expansion of parasite-specific T cells, there is likely to
be non-specific bystander activation. However, it remains unclear
whether T cells activated in a bystander manner can contribute to
ECM pathogenesis. Studies with ovalbumin-expressing PbA and
ovalbumin-specific transgenic T cells suggest that this is possible
since transfer of antigen-specific effector memory cells into mice
deficient of recombination-activating gene is not always sufficient
to induce ECM [61,62]. Indeed, in their study, Miyakoda et al
specifically analysed non-specific activation of CD8 T cells [62]
and found that while non-specific activation occurred it was at a
much lower level compared to specific activation.
Our results raise the intriguing and important question of why
the very efficient activation of CTLA-4 and PD-1 pathways in
C57BL/6 mice fails to protect them from acute immune
pathology. One interpretation is that T cell activation is so
extensive in ECM-susceptible C75BL/6 mice that positive T cell-
derived signals override physiological levels of immune inhibition
mediated by CTLA-4 and PD-1. Another interpretation of this
data is that in ECM-susceptible mice, CTLA-4 and PD-1 are
induced on highly activated T cells, but that their down-stream
signalling is impaired. Further studies are required to understand
why these potent immunoregulatory pathways are unable to
control T cell activation in animals with severe malarial
immunopathology and to determine whether these pathways play
roles in humans with cerebral malaria.
Strikingly, however, in vivo blockade of either CTLA-4 or PD-1/
PD-L1, but not PD-1/PD-L2, rendered otherwise resistant
BALB/c mice fully susceptible to ECM. Treated animals exhibited
characteristic neurological signs, their brains revealed the cardinal
features of ECM (haemorrhages, CD8+ T cell arrest and parasite
intravascular accumulation in the microvasculature) and there was
clear evidence of excessive systemic inflammation and T cell
activation. Thus, CTLA-4 and PD-1/PD-L1 play essential,
independent and non-redundant roles in preventing ECM in
resistant animals; this reinforces the urgent need to compare the
activation and down-stream effects of these pathways in humans
with or without severe malaria pathology. It is noteworthy that in
vivo blockade of either CTLA-4 did not affect the expression of
PD-1 on T cells; in vivo blockade of PD-1/PD-L1 did not affect the
expression of CTLA-4 on T cells (data not shown).
This study reveals – for the first time - evidence of subtle but
important differences in the effects of CTLA-4-mediated and PD-
1/PD-L1-mediated immune regulation during acute infections.
Infected animals treated with a-CTLA-4 always succumb to
infection significantly earlier than animals treated with a-PD-L1.
In addition, disruption of the CTLA-4 pathway led to higher levels
of T cell activation, significantly higher levels of circulating TNF
and IL-6 and, accordingly, earlier onset of ECM than did
blockade of the PD-1/PD-L1 pathway. Furthermore, we observed
that depletion of CD4+ T cells during PbA infection abrogated the
effects of a-CTLA-4 treatment but had no effect on a-PD-L1
treatment. Thus, our study suggests that CTLA-4 may be much
more effective than PD-1/PD-L1 at regulating CD4+ T cells
particularly in this experimental model of cerebral malaria,
although this hypothesis remains to be directly tested. Since
CD4+ T cells are essential for activation of CD8+ T cells and for
their arrest in the brain during ECM [40], effective regulation of
CD4+ T cells by CTLA-4 is likely to interrupt the chain of events
leading to ECM at a much earlier stage of infection than is
regulation of CD8+ T cell activity (by either CTLA-4 or PD-1/
PD-L1). It should be noted however, that in other models - such as
during M. tuberculosis infection - the PD-1/PD-L1 pathway has a
direct effect on CD4+ T cells in preventing T cell-driven
exacerbation of infection [63].
Our study thus raises the intriguing hypothesis that in the our
malaria model, CTLA-4 may be the primary regulatory pathway
for CD4+ T cells, thereby indirectly affecting CD8+ T cell
responses, whereas PD-1/PD-L1 preferentially and directly fulfils
this role for CD8+ T cells. This notion is consistent with published
data suggesting that CD8+ T cells are less dependent upon
costimulation through the CD28/CTLA-4/B7 axis than are
CD4+ T cells [64-66] and that blockade of the PD-1/PD-L1
pathway restores the effector functions of CD8+ T cells in the
absence of CD4+ T cell help [16,67]. Such a hypothesis is also
consistent with associations between PD-1/PD-L1 expression and
inability to control chronic viral infections such as LCMV [16]
and rabies [30], the failure of CTLA-4 blockade to ameliorate
CD8+ T cell exhaustion during LCMV infection [16], and the
preferential expression of CTLA-4 on CD4+ rather than CD8+
cells during HIV infection [17]. In addition, in LCMV-infected
mice that lacked CD4+ T cell-help, blockade of the PD-1/PD-L1
pathway reinvigorated the ‘helpless’ CD8+ T cells and allowed
them to function as effector cells [16].
Our observation that CTLA-4 blockade enhances susceptibility
to ECM in BALB/c mice but had no effect on the outcome of
infection in C57BL/6 mice is somewhat at odds with a previous
study in which CTLA-4 blockade was shown to increase
susceptibility to ECM, but in C57BL/6 mice [68]. The apparent
discrepancy may be explained by the unusually slow kinetics of
PbA infection in the study of Jacobs et al and by the fact that the
majority of the control mice survived for at least 20 days after
infection and did not develop ECM [68]; in our hands, and those
of most other investigators, PbA uniformly causes death from
ECM within 10 days in all C57BL/6 mice. It is not possible to
distinguish whether this reflects differences in susceptibility
between colonies of C57BL/6 mice or differences in virulence of
the parasite isolates (the PbA parasites used in the study of Jacobs et
al appear to be highly attenuated), but the message is clear: the
virulence of mouse/parasite combinations that do not normally
lead to ECM is significantly exacerbated by CTLA-4 blockade.
In addition to the very important observations emanating from
our direct side-by-side comparison of the roles of CTLA-4 and
PD-1/PD-L1, we have significantly extended our understanding of
the role of T cell regulatory pathways during malaria infection by
thoroughly characterising the effects of regulatory blockade on
both CD4+ and CD8+ T cells. The onset of ECM in BALB/c mice
following CTLA-4 or PD-1/PD-L1 blockade was accompanied by
elevated production of pro-inflammatory cytokines and by
increased migration of activated CD8+ T cells to the brain.
Neutralisation of IFN-c or depletion of CD8+ T cells during PbA
infection was shown to reverse the pathologic effects of the
inhibitory pathway blockade, confirming that the aetiology of
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ECM in the BALB/c mice is similar to that in susceptible C57BL/
6 mice [40]. These experiments not only identify the primary
targets of CTLA-4- and PD-1/PD-L1-mediated regulation as
being pro-inflammatory T cells, but also re-emphasise that CD8+
T cells and IFN-c are critical effectors of ECM.
In summary, we have revealed essential, independent and non-
redundant roles for CTLA-4/B-7 and PD-1/PD-L1 pathways in
regulating T cell-mediated pathology and host resistance to PbA-
induced ECM. Exploration of the relationship between T cell
regulatory pathways and outcome of malaria infection in humans
is clearly now a priority; such studies will need to go beyond simple
characterisation of CTLA-4 or PD-1 expression [69,70] and
consider the potential for genetic variation in the receptors, their
ligands and downstream signalling molecules to affect the outcome
of infection.
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